This would enable cells to enter the circulation and promote the forming of secondary tumors, making the tumor harder to treat.. A gene involved in the adhesion of cells is less active in breast tumors with an unhealthy prognosis than those that are less aggressive Physicians might be able to help to make early decisions on the very best treatment for breast cancers, today thanks to research published in Breasts Cancer Research. A gene involved in the adhesion of cells is definitely less active in breasts tumors with a poor prognosis than the ones that are less aggressive, researchers found. Measuring the activity of the ALCAM gene in major breast tumors could give physicians advanced warning about the likely clinical final result of the disease.This article can be republished with kind authorization from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Plan Record, search the archives, or join email delivery of in-depth coverage of health policy developments, discussions and debates. The Daily Health Plan Report is published for Kaisernetwork.org, a free program of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Organization and Kaiser Family Basis. All rights reserved.
Abell Foundation plays main role in BioMarker’s $1.7M private placement funding BioMarker Strategies announced today that it has raised $1.7 million in a private positioning funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program.